Rathbones Group PLC Maxcyte, Inc. Transaction History

Rathbones Group PLC

$17.8 Billion
Q2 2024

A detailed history of Rathbones Group PLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Rathbones Group PLC holds 262,741 shares of MXCT stock, worth $972,141. This represents 0.01% of its overall portfolio holdings.

Number of Shares

262,741

Previous 282,876 7.12%

Holding current value

$972,141

Previous $1.19 Million 13.16%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$3.63 - $5.0 $73,090 - $100,675	-20,135 Reduced 7.12%	262,741 $1.03 Million
Q1 2024 May 14, 2024	SELL	$3.94 - $5.38 $71,361 - $97,442	-18,112 Reduced 6.02%	282,876 $1.19 Million
Q4 2023 Feb 13, 2024	SELL	$2.6 - $5.24 $7,098 - $14,305	-2,730 Reduced 0.9%	300,988 $1.41 Million
Q3 2023 Nov 13, 2023	SELL	$3.02 - $5.1 $113,561 - $191,775	-37,603 Reduced 11.02%	303,718 $947,000
Q2 2023 Aug 04, 2023	SELL	$3.69 - $5.35 $78,460 - $113,757	-21,263 Reduced 5.86%	341,321 $1.57 Million
Q1 2023 May 12, 2023	SELL	$4.03 - $5.89 $20,166 - $29,473	-5,004 Reduced 1.36%	362,584 $1.79 Million
Q4 2022 Feb 14, 2023	SELL	$4.92 - $7.4 $93,548 - $140,703	-19,014 Reduced 4.92%	367,588 $2.01 Million
Q3 2022 Nov 03, 2022	SELL	$4.52 - $6.51 $48,725 - $70,177	-10,780 Reduced 2.71%	386,602 $2.5 Million
Q2 2022 Aug 12, 2022	SELL	$3.59 - $6.81 $38,718 - $73,445	-10,785 Reduced 2.64%	397,382 $1.83 Million
Q1 2022 May 11, 2022	SELL	$5.26 - $10.84 $104,432 - $215,217	-19,854 Reduced 4.64%	408,167 $2.89 Million
Q4 2021 Feb 10, 2022	SELL	$8.87 - $12.94 $170,898 - $249,314	-19,267 Reduced 4.31%	428,021 $4.38 Million
Q3 2021 Nov 04, 2021	BUY	$12.21 - $17.2 $5.46 Million - $7.69 Million	447,288 New	447,288 $5.43 Million

Others Institutions Holding MXCT

# of Institutions

118

Shares Held

65M

Call Options Held

600

Put Options Held

2.7K

View Full List

About MAXCYTE, INC.

Ticker MXCT
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 101,724,000
Market Cap $376M
Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...

More about MXCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rathbones Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Rathbones Group PLC with notifications on news.

Account

Rathbones Group PLC Maxcyte, Inc. Transaction History